candesartan has been researched along with Diabetes Mellitus in 19 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Diabetes Mellitus: A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Angiographically documented CAD patients with hypertension were randomly assigned to receive either candesartan-based (n= 1024) or non-ARB-based pharmacotherapy including angiotensin-converting enzyme-inhibitors (n = 1025)." | 9.14 | Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in ( Hagiwara, N; Haze, K; Honda, T; Hosoda, S; Kasanuki, H; Nagashima, M; Ogawa, H; Origasa, H; Sumiyoshi, T; Urashima, M; Yamaguchi, J, 2009) |
| "Candesartan is a selective angiotensin II Type I (AT(1)) receptor blocker which binds tightly to, and dissociates slowly from the receptor." | 6.42 | Candesartan for the treatment of hypertension and heart failure. ( Ostergren, J, 2004) |
| "Candesartan was more effective at reducing macrophage accumulation and collagen I abundance in plaques compared with rosuvastatin." | 5.35 | The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation. ( Boolell, V; Calkin, AC; Chew, C; Cooper, ME; Giunti, S; Jandeleit-Dahm, KA; Rajaram, YS; Sheehy, KJ, 2008) |
| "Candesartan was orally administered to 12-week-old rats for 21 days, and age-matched rats without the agent were used as the respective controls." | 5.31 | Candesartan inhibits carotid intimal thickening and ameliorates insulin resistance in balloon-injured diabetic rats. ( Daimon, M; Hirata, A; Igarashi, M; Kato, T; Ohnuma, H; Tominaga, M; Tsuchiya, H; Yamaguchi, H, 2001) |
| "Angiographically documented CAD patients with hypertension were randomly assigned to receive either candesartan-based (n= 1024) or non-ARB-based pharmacotherapy including angiotensin-converting enzyme-inhibitors (n = 1025)." | 5.14 | Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in ( Hagiwara, N; Haze, K; Honda, T; Hosoda, S; Kasanuki, H; Nagashima, M; Ogawa, H; Origasa, H; Sumiyoshi, T; Urashima, M; Yamaguchi, J, 2009) |
| "During the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial, patients with hypertension who received amlodipine had similar cardiovascular risks as those who received candesartan." | 3.88 | Long-term effects of antihypertensive therapy on cardiovascular events and new-onset diabetes mellitus in high-risk hypertensive patients in Japan. ( Ichihara, C; Kitao, H; Konda, M; Kuwabara, Y; Liu, J; Oba, K; Ueshima, K; Yasuno, S, 2018) |
| "This study investigated the relation between renal dysfunction and cardiovascular events in patients from the Challenge-DM Study (a large-scale investigation of Japanese diabetic patients with hypertension on candesartan therapy)." | 3.77 | Effects of renal dysfunction on cardiovascular events in diabetic patients with hypertension: challenge-DM Study subgroup analysis. ( Kawamori, R; Matsuoka, H; Saito, Y; Umemura, S, 2011) |
| "In 404 patients with left ventricular hypertrophy, a significantly larger decrease in left ventricular mass index 3 years after enrollment was observed in candesartan-based (n = 205) than amlodipine-based (n = 199) regimens (-22." | 2.73 | ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial. ( Fujimoto, A; Nakao, K; Ogihara, T; Saruta, T, 2008) |
| "Candesartan is a selective angiotensin II Type I (AT(1)) receptor blocker which binds tightly to, and dissociates slowly from the receptor." | 2.42 | Candesartan for the treatment of hypertension and heart failure. ( Ostergren, J, 2004) |
| " Further research is necessary to determine which AT1RBs and which dosing regimens are optimal." | 2.41 | Emerging role of angiotensin II type 1 receptor blockers for the treatment of endothelial dysfunction and vascular inflammation. ( Mancini, GB, 2002) |
| "Candesartan was more effective at reducing macrophage accumulation and collagen I abundance in plaques compared with rosuvastatin." | 1.35 | The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation. ( Boolell, V; Calkin, AC; Chew, C; Cooper, ME; Giunti, S; Jandeleit-Dahm, KA; Rajaram, YS; Sheehy, KJ, 2008) |
| "Treatment with candesartan, but not hydralazine, reduced these values to levels in db/m mice." | 1.35 | Urinary oxidative stress markers closely reflect the efficacy of candesartan treatment for diabetic nephropathy. ( Hashimoto, T; Hirawa, N; Imai, N; Ishigami, T; Kihara, M; Kitamura, H; Kiuchi, Y; Nomura, K; Tamura, K; Toya, Y; Umemura, S; Yasuzaki, H; Yoshida, S, 2009) |
| "Diabetic retinopathy is the most common microvascular complication caused by diabetes mellitus and is a leading cause of vision loss among working-age adults in developed countries." | 1.35 | Angiotensin AT1 receptor antagonism ameliorates murine retinal proteome changes induced by diabetes. ( Bursell, D; Clermont, AC; Feener, EP; Gao, BB; Phipps, JA, 2009) |
| "Candesartan treatment completely suppressed the increases of p21, p27, p53 and Rb." | 1.33 | Angiotensin II receptor antagonist attenuates expression of aging markers in diabetic mouse heart. ( Izumi, T; Kosugi, R; Machida, Y; Shioi, T; Takahashi, K; Watanabe-Maeda, K; Yoshida, Y, 2006) |
| "Candesartan was orally administered to 12-week-old rats for 21 days, and age-matched rats without the agent were used as the respective controls." | 1.31 | Candesartan inhibits carotid intimal thickening and ameliorates insulin resistance in balloon-injured diabetic rats. ( Daimon, M; Hirata, A; Igarashi, M; Kato, T; Ohnuma, H; Tominaga, M; Tsuchiya, H; Yamaguchi, H, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 16 (84.21) | 29.6817 |
| 2010's | 3 (15.79) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, J | 1 |
| Yasuno, S | 1 |
| Oba, K | 2 |
| Konda, M | 1 |
| Ichihara, C | 1 |
| Kitao, H | 1 |
| Kuwabara, Y | 1 |
| Ueshima, K | 2 |
| Calkin, AC | 1 |
| Giunti, S | 1 |
| Sheehy, KJ | 1 |
| Chew, C | 1 |
| Boolell, V | 1 |
| Rajaram, YS | 1 |
| Cooper, ME | 1 |
| Jandeleit-Dahm, KA | 1 |
| Ogihara, T | 2 |
| Fujimoto, A | 1 |
| Nakao, K | 2 |
| Saruta, T | 2 |
| Yoshida, S | 1 |
| Hashimoto, T | 1 |
| Kihara, M | 1 |
| Imai, N | 1 |
| Yasuzaki, H | 1 |
| Nomura, K | 1 |
| Kiuchi, Y | 1 |
| Tamura, K | 1 |
| Ishigami, T | 1 |
| Hirawa, N | 1 |
| Toya, Y | 1 |
| Kitamura, H | 1 |
| Umemura, S | 2 |
| Kasanuki, H | 1 |
| Hagiwara, N | 1 |
| Hosoda, S | 1 |
| Sumiyoshi, T | 1 |
| Honda, T | 1 |
| Haze, K | 1 |
| Nagashima, M | 1 |
| Yamaguchi, J | 1 |
| Origasa, H | 1 |
| Urashima, M | 1 |
| Ogawa, H | 1 |
| Gao, BB | 1 |
| Phipps, JA | 1 |
| Bursell, D | 1 |
| Clermont, AC | 1 |
| Feener, EP | 1 |
| Kawamori, R | 1 |
| Matsuoka, H | 1 |
| Saito, Y | 1 |
| Nishida, Y | 1 |
| Takahashi, Y | 1 |
| Nakayama, T | 1 |
| Soma, M | 1 |
| Asai, S | 1 |
| Mancini, GB | 1 |
| Sato, N | 1 |
| Kase, H | 1 |
| Kato, T | 2 |
| Kasai, K | 1 |
| Evans, L | 1 |
| Ostergren, J | 1 |
| Kosugi, R | 1 |
| Shioi, T | 1 |
| Watanabe-Maeda, K | 1 |
| Yoshida, Y | 1 |
| Takahashi, K | 1 |
| Machida, Y | 1 |
| Izumi, T | 1 |
| Momomura, S | 1 |
| Ichihara, A | 1 |
| Kaneshiro, Y | 1 |
| Takemitsu, T | 1 |
| Sakoda, M | 1 |
| Itoh, H | 1 |
| Kinugawa, S | 1 |
| Fukui, T | 1 |
| Fukiyama, K | 1 |
| Sato, T | 1 |
| Ruilope, L | 1 |
| Igarashi, M | 1 |
| Hirata, A | 1 |
| Yamaguchi, H | 1 |
| Tsuchiya, H | 1 |
| Ohnuma, H | 1 |
| Tominaga, M | 1 |
| Daimon, M | 1 |
6 reviews available for candesartan and Diabetes Mellitus
| Article | Year |
|---|---|
Emerging role of angiotensin II type 1 receptor blockers for the treatment of endothelial dysfunction and vascular inflammation.
Topics: Acrylates; Aged; Antihypertensive Agents; Benzimidazoles; Biomarkers; Biphenyl Compounds; Coronary A | 2002 |
[Effect of angiotensin II type 1 receptor antagonist on oxidative stress markers in type 2 diabetic patients with hypertension].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Diabe | 2003 |
Candesartan for the treatment of hypertension and heart failure.
Topics: Administration, Oral; Benzimidazoles; Biphenyl Compounds; Diabetes Mellitus; Double-Blind Method; Dr | 2004 |
[CHARM].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2006 |
[Diabetic heart disease].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; B | 2007 |
RAS blockade: new possibilities in the treatment of complications of diabetes.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazo | 2000 |
3 trials available for candesartan and Diabetes Mellitus
| Article | Year |
|---|---|
ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2008 |
Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angiotensin II Type 1 Receptor Blockers; Benzimidaz | 2009 |
Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood | 2008 |
10 other studies available for candesartan and Diabetes Mellitus
| Article | Year |
|---|---|
Long-term effects of antihypertensive therapy on cardiovascular events and new-onset diabetes mellitus in high-risk hypertensive patients in Japan.
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cardi | 2018 |
The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Benzimidazoles; Biphenyl Compou | 2008 |
Urinary oxidative stress markers closely reflect the efficacy of candesartan treatment for diabetic nephropathy.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Antihype | 2009 |
Angiotensin AT1 receptor antagonism ameliorates murine retinal proteome changes induced by diabetes.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Benzimidazoles; Biphenyl Compounds; Dia | 2009 |
Effects of renal dysfunction on cardiovascular events in diabetic patients with hypertension: challenge-DM Study subgroup analysis.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cardiov | 2011 |
Comparative effect of olmesartan and candesartan on lipid metabolism and renal function in patients with hypertension: a retrospective observational study.
Topics: Aged; Angiotensin II Type 2 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Urea Nitrog | 2011 |
American Diabetes Association--63rd Scientific Sessions. Preclinical data. 13-17 June 2003, New Orleans, LA, USA.
Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Chemokine CCL2; Diabet | 2003 |
Angiotensin II receptor antagonist attenuates expression of aging markers in diabetic mouse heart.
Topics: Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biomarkers; Biphenyl Compou | 2006 |
Benefits of candesartan on arterial and renal damage of non-diabetic hypertensive patients treated with calcium channel blockers.
Topics: Aged; Albuminuria; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Calcium Channel Bloc | 2006 |
Candesartan inhibits carotid intimal thickening and ameliorates insulin resistance in balloon-injured diabetic rats.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Carotid Artery, Commo | 2001 |